

Valeant Pharmaceuticals Stock Has Plunged 86% in 2016. When Will the Nightmare End?

Borrowing heavily to acquire drugs and then raising their prices was a fantastic business model for Valeant Pharmaceuticals -- until suddenly it wasn't. It appears the company's ability to generate increasing profits through price hikes is evaporating along with its ability to service the staggering \$30.4 billion in debt on its balance sheet. It's no wonder has fallen stock about 86% so far this year. Investors are right to wonder if the nightmare is almost over, or just beginning.

Date: 18 Sep 15 - 30 Dec 16

Company Statistics

Companies affected:

Valeant Pharmaceuticals- Steinbach, MB. - VRX

Operations: Commercial & Industrial

Followers: 556

Website: <http://www.valeantcanada.com>


Description:

Valeant Pharmaceuticals is a multinational specialty pharmaceutical company based in Laval, Canada. It develops, manufactures, and markets a broad range of pharmaceutical products primarily in the areas of dermatology ...


During the period 18 Sep 15 - 30 Dec 16:

- 12 articles mentioning VRX were published
- Maximum stock price was \$245.82
- Minimum stock price was \$13.00
- Initial stock price was \$242.14
- Final stock price was \$14.52
- On average:
 - 0 posts were made per day
 - there were NaN likes per post
 - there were NaN comments per post

Global Impact Heat Map



Company Stock Graph



Top News Headlines

Sat 17 Dec 16

Buckfast, malt extract and antisocial Daleks | Letters

You report that the European finance ministers have frozen the Greek debt relief deal (15 December). The reason was the Greek government had made ...

Tue 26 Jul 16

McDonnell and Corbyn called for protection for pharmaceuticals in 2014

Jeremy Corbyn and John McDonnell jointly called for the UK to remain "a world leader" in pharmaceuticals research two years ago, it has emerged, a ...

Tue 22 Mar 16

Valeant's 'simple philosophy' comes undone in the real world

"Be decisive, stay balanced, and always find ways to grow," trumpeted the front page of Valeant's last annual report, a yearly exercise in bragging ...

Fri 18 Dec 15

Pharmaceutical (and Wu-Tang) villain Martin Shkreli has courted controversy

Brooklyn bad boy Martin Shkreli has never been far from controversy and that's just the way he likes it, normally. The 32-year-old became a Wall ...

Wed 9 Dec 15

Recovery 'too reliant on consumer debt' as BCC downgrades forecast

Britain's economic recovery remains too reliant on debt-fuelled consumer spending, a leading UK business organisation has warned, as it downgraded ...